Eli Lilly CEO Says Drugmaker Won’t Rehash Old Alzheimer’s Data

(Bloomberg) -- Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.